One of the final hurdles in front of Amgen's $28 billion acquisition of Horizon Pharma has fallen after an agreement was reached between the two companies and the Federal
Horizon Pharma's executive vice president, head of research and development, and chief scientific officer talks to pharmaphorum about what inspires her in life sciences,
Novartis has struck another deal to build its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Oncology
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.